Market Overview

UPDATE: Mizuho Securities USA Initiates Coverage On Epizyme Inc On Epigenetics Pure Play


In a report published Friday, Mizuho Securities USA analyst Peter Lawson initiated coverage on Epizyme Inc (NASDAQ: EPZM) with a Buy rating and $35.00 price target.

In the report, Mizuho Securities USA noted, “We are initiating coverage of shares of Epizyme with a Buy rating and a price target of $35. Epizyme is a pure-play on epigenetics, a gene regulatory system that can be exploited to target cancer cells. While the company's pipeline is early phase, valuation is supported by a series of significant biopharmaceutical partners, a series of 4Q14 Phase I readouts, and a platform and IP for further discovery.”

Epizyme closed on Thursday at $28.20.

Latest Ratings for EPZM

Jan 2019UpgradesMarket PerformOutperform
Nov 2018MaintainsEqual-WeightEqual-Weight
Sep 2018Initiates Coverage OnMarket Perform

View More Analyst Ratings for EPZM
View the Latest Analyst Ratings

Posted-In: Mizuho Securities USA Peter LawsonAnalyst Color Initiation Analyst Ratings


Related Articles (EPZM)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Morning Market Losers

Citigroup Offers Up A Pair Trade For AllianceBernstein Holding LP And Artisan Partners Asset Management Inc